Exhibit 4.36 DEVELOPMENT AGREEMENT betweenLEO PHARMA A/S of Industriparken 55, DK-2750 Ballerup, Denmark (hereinafterreferred to as "LEO") --- andGALEN (CHEMICALS) LIMITED of 4 Adelaide Street, Dun Laoghaire, Co. Dublin,Ireland (hereinafter referred to as "GALEN").Capitalized terms not otherwise defined herein shall have the meanings set forthin Article I of this Agreement.WHEREAS Bristol-Myers Squibb Company (BMS) has entered into a co-promotionagreement with GALEN regarding Dovonex(R) Product in the Territory (the"Co-promotion Agreement").WHEREAS GALEN and BMS have entered into an option agreement (the "OptionAgreement") in which GALEN has options to acquire all of BMSs rights and toassume BMSs obligations (the "Option") under the agreement dated September 28,1989 between BMS (as successor to E.R. Squibb Sons Inc.) and LEO, as amendedJuly 6, 1992 and April 8, 1993 and as of the date hereof and the Product SupplyAgreement between Bristol-Myers Squibb Company and LEO dated as of April 8, 1993(each as may be amended or supplemented by the parties in the future,collectively, the "BMS Agreements"); andWHEREAS BMS has given up its rights under the BMS Agreements to a pharmaceuticalpreparation containing both the Compound and Betamethasone Dipropionate in anointment (the "Combination Product") as of the date hereof; andWHEREAS LEO has developed and owns proprietary information regarding theCombination Product, and has filed a patent application for the CombinationProduct; andWHEREAS GALEN has marketing expertise within the dermatological field; andWHEREAS LEO and GALEN have entered into a License and Supply Agreement dated asof even date herewith between LEO and GALEN regarding the Combination Product(the "Dovobet(R) Agreement") and subject to the coming into force of thatAgreement under its terms, LEO has appointed GALEN as its exclusive distributorin the Territory of the Combination Product expected to be marketed under thetrademark Dovobet(R); andWHEREAS GALEN and LEO have entered into a License and Supply Agreement dated asof even date herewith pursuant to which GALEN will be the exclusive distributorof Dovonex(R) Product in the Territory subsequent to the exercise of the Optionby GALEN and the acquisition of BMSs rights and assumption of BMSs obligationsunder the BMS Agreements by GALEN (the "Dovonex(R) Agreement"); andWHEREAS GALEN, if the FDA mandates an additional pivotal phase III clinicaltrial for the Combination Product, will financially support LEO;NOW THEREFORE the Parties hereby agree as follows:I - DEFINITIONS1.1 "AB rated" means, with respect to any Product (as defined in the Dovonex(R) Agreement), a pharmaceutical product which is an AB-rated equivalent to the Product, as defined in the 22nd edition of Approved Drug Products with Therapeutic Equivalence Evaluations issued by the United States Department of Health and Human Services.1.2 "Action or Proceeding" means any action, suit, proceeding, arbitration or Governmental or Regulatory Authority action, notification, investigation or audit.1.3 "Affiliate" means, with respect to any Person, any Person which, directly or indirectly, controls, is controlled by, or is under common control with, the specified Person. For purposes of this definition, the term "control" as applied to any Person, means the possession, directly or indirectly, of at least fifty-one per cent (51%) of the power to direct or cause the direction of the management of that Person, whethersbsp;through ownership of voting securities or otherwise.1.4 "Agreement" means this Development Agreement between LEO and GALEN.1.5 "Compound" means the compound Calcipotriene, a vitamin D analogue with the formula C27H4003. 21.6 "Dovonex(R) Product" means the Compound marketed in the Territory under the trademark Dovonex(R).1.7 "FDA" means the United States Food and Drug Administration.1.8 "GALEN Information" means any information (including, but not limited to, technical improvements, financial and marketing information) developed, made and/or generated by GALEN relating to and made as a result of its work with the Combination Product.1.9 "Governmental or Regulatory Authority" means any court, tribunal, arbitrator, agency, commission, official or other instrumentality of the United States or any relevant country, state, province, county, city or other political subdivision.1.10 "IND" means the Investigational New Drug Application, as defined by the United States Federal Food, Drug and Cosmetic Act and applicable regulations promulgated thereunder as amended from time to time, filed in the United States, for the Combination Product.1.11 "Laws" means all laws, statutes, rules, regulations, ordinances and other pronouncements having the effect of law of any relevant Governmental or Regulatory Authority.1.12 "LEO Logo Guidelines" means the guidelines for use of the LEO name and the Assyrian Lion logo attached to the Dovobet(R) Agreement.1.13 "LEO Product Branding" means the Trademark, the LEO name, the Assyrian Lion, the LEO Logo Guidelines, the LEO Product Concept and any domain names or websites related to the Combination Product in the Territory.1.14 "LEO Product Concept" means the global design concept for packaging and promotional materials related to the Combination Product developed by LEO.1.15 "Losses" means any and all damages, fines, fees, penalties, deficiencies, losses and expenses (including without limitation interest, court costs, reasonable fees of attorneys, accountants and other experts or other expenses of litigation or other proceedings or of any claim, default or assessment).1.16 "Master Agreement" means the Master Agreement dated as of even date herewith between LEO and GALEN.1.17 "NDA" means a New Drug Application filed with the FDA for the Combination Product, requesting permission to place a drug on the market in accordance with 21 C.F.R. Part 314 and all supplements filed pursuant to the requirements of the FDA, including all documents, data and other 3 information concerning the Combination Product which are necessary for FDA approval to market a product in the United States.1.18 "Party" means GALEN or LEO, as the case may be, and "Parties" means GALEN and LEO.1.19 "Person" means any individual, firm, corporation, partnership, limited liability company, trust, joint venture, Governmental or Regulatory Authority or other entity or organization.1.20 "Technical Information" means all information in the possession of LEO and/or its Affiliates, and any information transferred from BMS to GALEN, regarding preclinical, chemical-pharmaceutical and clinical data or other scientific information (including specifications, master batch records, analytical methods including validation protocol and the drug master file), or secret know-how about the Combination Product including, but not limited to marketing know-how and show-how or uses for the Combination Product in the possession of LEO regarding the Combination Product necessary for GALEN to fulfil its obligations under the Agreement.1.21 "Territory" means the fifty (50) states of the United States of America, the District of Columbia, its territories and current possessions.1.22 "Trademark" means the trademark Dovobet(R) or any other trademark LEO may select for the Combination Product.II - WORK BY LEO2.1 LEO has performed any and all preclinical, clinical and other studies necessary to obtain marketing approval for the Combination Product in Europe and has borne all costs and expenses associated therewith. Furthermore, LEO will perform any and all additional studies, required specifically by the FDA and will bear all costs and expenses associated therewith except for the obligation of GALEN described in Article 3.1. A development plan is attached as Appendix I2.2 LEO is responsible for obtaining approval of the NDA in the United States.III - OBLIGATIONS OF GALEN3.1 If the FDA mandates that a second pivotal phase III clinical trial for the Combination Product is required for registration in the United States, GALEN agrees to pay 50% of the reasonable costs for 4 said study, such costs to be invoiced by LEO on a quarterly basis. The payments are non-refundable.3.2 GALEN will provide reasonable assistance to LEO in its endeavours to obtain approval of the NDA in the United States.3.3 Within thirty (30) days after the date hereof, GALEN will pay to LEO US5,000,000 (five million United States dollars) to reimburse LEO for a portion of the actual development costs that have been incurred by LEO. This payment is non-refundable.IV - INDEMNIFICATION4.1 LEO shall indemnify and hold GALEN and its agents, directors, officers and employees and representatives harmless from and against any and all Losses which they may at any time incur by reason of any Action or Proceeding brought by any Governmental or Regulatory Authority or other third party against GALEN arising out of or resulting from (a) any misrepresentation, breach of warranty or non-fulfilment of or failure to perform any agreement or covenant made by LEO in this Agreement, (b) the use of the Combination Product in any clinical trial, or (c) any other negligent act or omission of LEO.4.2 GALEN shall indemnify and hold LEO and its agents, directors, officers and employees and representatives harmless from and against any and all Losses which they may at any time incur by reason of any Action or Proceeding brought by any Governmental or Regulatory Authority or other third party against LEO arising out of or resulting from (a) any misrepresentation, breach of warranty or non-fulfilment of or failure to perform any agreement or covenant made by GALEN in this Agreement, or (b) any other negligent act or omission of GALEN.4.3 The obligation of the Parties in this Article IV shall survive the expiration or earlier termination of this Agreement to the extent permitted by applicable Law.4.4 In any case under this Article IV, where GALEN or LEO is to indemnify the other, the control of the defence of any Action or Proceeding and negotiations for settlement and compromise thereof, shall repose with the indemnifying Party, except that nothing in this paragraph shall be construed to relieve either Party hereto of the obligation to give the other all reasonable co-operation, assistance and authority necessary to permit full and complete defence of any Action or Proceeding; provided, however, that no Party will settle any of such claims without consent of the other Party; however, such consent shall not be unreasonably withheld. Both Parties shall, if desired, be allowed to participate, at their own expense, directly or through a representative e.g. their product liability insurers, in any Action or Proceeding. 5V - CONFIDENTIALITY5.1 All Technical Information disclosed to GALEN and all GALEN Information disclosed to LEO shall be considered confidential regardless of designation, and shall not be disclosed by the receiving Party to any third party or used outside the scope of this Agreement without the prior written consent of the disclosing Party except to a duly authorised Governmental or Regulatory Authority in connection with the registration or regulation of the Combination Product or if otherwise required by Law. In the event that a Party is asked to disclose any confidential information to a Governmental or Regulatory Authority, such Party will - if possible - notify the nondisclosing Party sufficiently prior to making such disclosure so as to allow the nondisclosing Party adequate time to take whatever action it may deem to be appropriate to protect the confidentiality of the information. The obligation not to disclose Technical Information and GALEN Information shall not apply to (a) any information that it now or later becomes publicly available through no fault of the receiver, its officers, employees or agents; (b) any information that the receiver obtains from a third party not under a confidentiality obligation to the discloser with respect to such information; (c) any information that the receiver already has in its possession as indicated in its written records; and (d) any information that is independently developed or created by the receiver.5.2 Each Party shall keep the terms of this Agreement confidential and shall not disclose the samebbsp;to any third party other than (i) by agreement of the Parties hereto, or (ii) as required by Law or stock exchange regulation or an order of a competent Governmental or Regulatory Authority; provided that prior to disclosure pursuant to (ii) above, the disclosing Party shall - if possible - notify the nondisclosing Party sufficiently prior to making such disclosure so as to allow the nondisclosing Party adequate time to take whatever action it may deem to be appropriate to protect the confidentiality of the information.5.3 Neither Party shall make any press release or other public announcement or other disclosure to third Parties relating to this Agreement without the prior consent of the other Party, which consent shall not be unreasonably withheld, except where required by applicable Law; provided that prior to disclosure, the disclosing Party shall notify the nondisclosing Party sufficiently prior to making such disclosure so as to allow the nondisclosing Party adequate time to take whatever action it may deem to be appropriate to protect the confidentiality of the information.5.4 This Article V shall survive the termination of this Agreement for a period of ten (10) years, provided, however, that following the termination of this Agreement LEO shall be free to use all data, information or other confidential information relating to the Combination Product and following termination of this Agreement, GALEN shall be free to use all GALEN Information. 6VI - COMPLIANCE WITH LAWSBoth LEO and GALEN shall observe all applicable Laws in effect in fulfillingtheir obligations under this Agreement.VII - TERM AND TERMINATION - CONSEQUENCES OF TERMINATION7.1 This Agreement will be effective when signed by both Parties provided that the Co-promotion Agreement and the Option Agreement have been signed and have come into force and provided also that said agreements do not prohibit GALEN from entering into the Dovonex(R) Agreement and the Dovobet(R) Agreement.7.2 This Agreement shall terminate if (a) the Dovonex(R) Agreement is terminated by LEO pursuant to Articles 15.4, 15.7 or 15.8 thereof or (b) the Dovonex(R) Agreement is terminated by LEO pursuant to Article 15.2 thereof in the event that GALEN has not exercised the Option for reasons not including that (i) the aggregate turnover of the Products in the U.S. during the period 1 July 2004 - 30 June 2005, as measured by IMSHealth, is equal to or less than US50,000,000 (fifty million dollars) or (ii) on or prior to August 1, 2005 a generic product that is AB rated to any Product (as defined in the Dovonex(R) Agreement) is approved by the FDA and has become commercially available, provided, for purposes of this subclause (ii), that GALEN has not provided assistance to the holder of the registration for the AB rated product to obtain such registration, or (c) the Dovobet(R) Agreement comes into force and GALEN has fulfilled its obligations under this Agreement, unless prior terminated in accordance with any of the provisions hereof.7.3 In the event that one of the Parties hereto materially defaults or breaches any of the provisions of this Agreement, the other Party shall have the right to terminate this Agreement upon sixty (60) days written notice, provided, however, that if the Party in default, within the sixty day period referred to, remedies the said default or breach, the Agreement shall continue in full force and effect.7.4 In the event of termination of this Agreement under the provisions of this Article VII GALEN shall not be relieved of the duty and obligations to pay in full, any payments due and unpaid at the effective date of such termination. In such event GALEN shall: (a) return any and all Technical Information and any other information relating to the Combination Product provided to GALEN and shall make no further use thereof; (b) cease to make use of the Trademark, the other LEO Product Branding and all other information related to the Combination Product, and all rights in the Trademark, the other 7 LEO Product Branding and all other information relating to the Combination Product will promptly revert to LEO and be transferred to LEO; (c) if GALEN is then the owner of any patents specifically related to the Combination Product, GALEN shall transfer such ownership to LEO, except for LEO being in breach in which case GALEN will sell said patents and LEO will purchase said patents at a price equal to the expenses GALEN has borne in relation to developing, establishing and maintaining said patent rights; (d) if GALEN is then the owner of any patents, which in part relates to the Combination Product then LEO, its Affiliates and partners shall have a royalty free license to such patents for the term of the patents; (e) if GALEN is then the owner of any data related to the Combination Product, including, but not limited to, any data related to any study performed under this Agreement such data shall be transferred to LEO. At such time, LEO shall have the right, but not the obligation, to have assigned to LEO any third party clinical agreement then pending; (f) GALEN shall transfer the NDA, the IND and any other relevant registrations related to the Combination Product held by GALEN, if any, to LEO or its designee. In the event that LEO terminates this Agreement pursuant to Article 7.3 or Article 7.2(a) or (b), the transfers required under Article 7.4 (a), (b), (c), (e) and (f) shall be made free of charge to LEO. Otherwise, the costs of transfers shall be split evenly between the parties.VIII - ASSIGNABILITYThis Agreement shall be binding upon, and shall inure to the benefit ofsuccessors of the Parties hereto, or to any assignee of all of the goodwill andentire business assets of a Party hereto relating to pharmaceuticals, but shallnot otherwise be assignable without the prior written consent of the otherParty.For the avoidance of doubt, LEO agrees and acknowledges that GALEN may performany or all of its obligations under this agreement through its U.S. Affiliates,Warner Chilcott, Inc..IX - AMENDMENT OF AGREEMENT; WAIVER; SEVERABILITY9.1 This Agreement shall not be changed or modified orally.9.2 Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument 8 duly executed by or on behalf of the Party waiving such term or condition. No waiver by either Party of any term or condition of this Agreement, in any one or more instances, shall be deemed to be or construed as a waiver of the same or any other term or condition of this Agreement on any future occasion. All remedies, either under this Agreement or by Law or otherwise afforded, will be cumulative and not alternative.9.3 If any provision of this Agreement is held to be illegal, invalid or unenforceable under any applicable present or future Law, and if the rights or obligations of any Party hereto under this Agreement will not be materially and adversely affected thereby, (a) such provision will be fully severable, (b) this Agreement will be construed and enforced as if such illegal, invalid or unenforceable provision had never comprised a part hereof, (c) the remaining provisions of this Agreement will remain in full force and effect and will not be affected by the illegal, invalid or unenforceable provision or by its severance herefrom and (d) in lieu of such illegal, invalid or unenforceable provision, the Parties will add as a part of this Agreement, a legal, valid and enforceable provision as similar in terms to such illegal, invalid or unenforceable provision as may be possible.X - STATUS OF PRIOR AGREEMENTSThis Agreement together with the Master Agreement, the Dovonex(R) Agreement andthe Dovobet(R) Agreement constitute the entire agreement between the Partieshereto with respect to the subject matter and supersede all previous agreements,whether written or oral.XI - FORCE MAJEUREThe occurrence of an event which materially interferes with the ability of aParty to perform its obligations or duties hereunder which is not within thereasonable control of the Party affected, not due to malfeasance, and whichcould not with the exercise of due diligence have been avoided ("Force Majeure")including, but not limited to, fire, accident, labour difficulty, strike, riot,civil commotion, act of God, delay or errors by shipping companies or change inLaw shall not excuse such Party from the performance of its obligations orduties under this Agreement, but shall merely suspend such performance duringthe continuation of Force Majeure. The Party prevented from performing itsobligations or duties because of Force Majeure shall promptly notify the otherParty hereto (the "Other Party") of the occurrence and particulars of such ForceMajeure and shall provide the Other Party, from time to time, with its bestestimate of the duration of such Force Majeure and with notice of thetermination thereof. The Party so affected shall use its best efforts to avoidor remove such causes of non-performance. Upon termination of Force Majeure, theperformance of any suspended obligation or duty shall promptly recommence.Neither Party shall be liable to the Other Party for any direct, indirect,consequential, incidental, special, punitive or exemplary damages arising out ofor relating to the 9suspension or termination of any of its obligations or duties under thisAgreement by reason of the occurrence of Force Majeure. In the event that ForceMajeure has occurred and is continuing for a period of at least six (6) months,the Other Party shall have the right to terminate this Agreement upon thirty(30) days notice.XII - PARTNERSHIP/AGENCY; THIRD PARTIES12.1 None of the provisions of this Agreement shall be deemed to constitute the relationship of partnership or agency between the Parties, and neither Party shall have any authority to bind the other Party in any way except as provided in this Agreement.12.2 The Parties agree that no third party which is not a Party to this Agreement is intended to benefit from or shall have any right to enforce any provision of this Agreement.XIII - GOVERNING LAWTHIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THEINTERNAL LAWS OF THE STATE OF NEW YORK APPLICABLE TO AGREEMENTS MADE AND TO BEPERFORMED ENTIRELY WITHIN SUCH STATE, WITHOUT REGARD TO THE CONFLICTS OF LAWPRINCIPLES OF SUCH STATE OTHER THAN SECTIONS 5-1401 OF THE NEW YORK GENERALOBLIGATIONS LAW.Each Party irrevocably submits to the exclusive jurisdiction of (a) the SupremeCourt of the State of New York, New York County, and (b) the United StatesDistrict Court for the Southern District of New York, for the purposes of anysuit, action or other proceeding arising out of this Agreement or anytransaction contemplated hereby or thereby. Each Party agrees to commence anysuch action, suit or proceeding either in the United States District Court forthe Southern District of New York or if such suit, action or other proceedingmay not be brought in such court for jurisdictional reasons, in the SupremeCourt of the State of New York, New York County. Each Party further agrees thatservice of any process, summons, notice or document by registered mail to suchPartys respective address set forth above shall be effective service of processfor any action, suit or proceeding in New York with respect to any matters towhich it has submitted to jurisdiction in this Article XIII. Each Partyirrevocably and unconditionally waives any objection to the laying of venue ofany action, suit or proceeding arising out of this Agreement or the transactionscontemplated hereby and thereby in (i) the Supreme Court of the State of NewYork, New York County or (ii) the United States District Court for the SouthernDistrict of New York, and hereby and thereby further irrevocably andunconditionally waives and agrees not to plead or claim in any such court thatany such action, suit or proceeding brought in any such court has been broughtin an inconvenient forum. 10Each Party hereto hereby waives to the fullest extent permitted by applicableLaw, any right it may have to a trial by jury in respect to any litigationdirectly or indirectly arising out of, under or in connection with thisAgreement.XIV - NOTICESAny notice hereunder shall be deemed to be sufficiently given if sent byregistered mail or by fax followed by mail to:In the case of GALEN: GALEN (CHEMICALS) LIMITED 4 Adelaide Street Dun Laoghaire, Co. Dublin Ireland Fax: 353 1 214 8477With a copy to: Galen Holdings PLC Att. Chief Executive Officer 100 Enterprise Drive, Suite 280 Rockaway, New Jersey 07866 USA Fax: 1 973 442 3362In the case of LEO: LEO PHARMA A/S Att. CEO, President Industriparken 55 DK-2750 Ballerup Denmark Fax: 45 44 64 15 80or such other address as the receiver shall have last furnished to the sender. 11IN WITNESS WHEREOF the Parties hereto have caused this Agreement to be dulyexecuted in duplicate by their authorised officers as of the date last belowwritten.Rockaway, April ____, 2003 Ballerup, April ____, 2003GALEN (CHEMICALS) LIMITED LEO Pharma A/S------------------------------ ----------------------------Name: Roger M. Boissonneault Name:Title: Director Title: